A preclinical study in which human tumor cells were co-cultured with SIRPαFc (TTI-621) that binds to CD47 demonstrated the anti-tumor effect of CD47-blockade on various solid and hematologic malignancies [58]. The gene discussed is CD47; the disease is neoplasm.